Trials / Recruiting
RecruitingNCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
The CAROLYN Trial: Lisocabtagene Maraleucelas First-Line Therapy for Primary Central Nervous System Lymphoma (PCNSL) in Transplant-Ineligible Patients
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 65 (estimated)
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | Specified dose on specified days |
| DRUG | Methotrexate | Specified dose on specified days |
| DRUG | Procarbazine | Specified dose on specified days |
| DRUG | Temozolomide | Specified dose on specified days |
| BIOLOGICAL | Liso-cel | Specified dose on specified days |
| DRUG | Fludarabine | Specified dose on specified days |
| DRUG | Cyclophosphamide | Specified dose on specified days |
| DRUG | Calcium folinate | Specified dose on specified days |
Timeline
- Start date
- 2025-11-06
- Primary completion
- 2028-01-09
- Completion
- 2028-12-10
- First posted
- 2025-06-11
- Last updated
- 2026-03-24
Locations
82 sites across 3 countries: United States, France, Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07015242. Inclusion in this directory is not an endorsement.